Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
The role of Toll-like receptor 4 as an upstream modulator of poor outcome in experimental subarachnoid hemorrhage.
EF 2014-15
Résumé
Subarachnoid hemorrhage (SAH) only comprises 7% of stroke cases worldwide, yet due to its relatively early age of onset and poor outcome, its socioeconomic impact rivals that of ischemic stroke, the most common stroke variant. Poor outcome is largely attributed to a number of secondary events, including early brain injury, microcirculatory dysfunction and inflammation. The focus for the proposed project centers around inflammation, as increased levels of tumour necrosis factor-alpha, interleukin-1-beta, and interleukin-6 have been shown to correlate strongly with poor outcome in SAH patients. It is unclear what causes this cytokine upregulation, but evidence suggests that Toll-like receptor 4 (TLR4) signalling may be a key player. TLR4 signalling is known to activate cytokine production by macrophages and microglia, though it may also do this in endothelial, smooth muscle, and neuronal cells. Additionally, TLR4 has been implicated in poor outcome in other cerebrovascular disorders, such as intracerebral hemorrhage and ischemic stroke, with genetic and pharmacological suppression of the receptor significantly improving outcome. Our goals are to 1) elucidate the role of TLR4 signalling in poor outcome after SAH using TLR4-knockout mice, 2) identify the key cell types and molecules involved in the pro-inflammatory response to SAH using immunohistochemistry, flow cytometry, qRT-PCR, and ELISA cytokine array, and 3) to demonstrate that pharmacological inhibition of this pathway is feasible and beneficial for animals undergoing experimental SAH. We anticipate that this work will provide more support for the role of TLR4 in mediating the secondary complications after SAH.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
331381
Name
Brathwaite Shakira
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The role of Toll-like receptor 4 as an upstream modulator of poor outcome in experimental subarachnoid hemorrhage.
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Delayed Cerebral Ischemia (Dci); Inflammation; Microglia; Subarachnoid Hemorrhage (Sah); Toll-Like Receptor 4 (Tlr4); Tumor Necrosis Factor Alpha (Tnfa)
Abstract
Subarachnoid hemorrhage (SAH) only comprises 7% of stroke cases worldwide, yet due to its relatively early age of onset and poor outcome, its socioeconomic impact rivals that of ischemic stroke, the most common stroke variant. Poor outcome is largely attributed to a number of secondary events, including early brain injury, microcirculatory dysfunction and inflammation. The focus for the proposed project centers around inflammation, as increased levels of tumour necrosis factor-alpha, interleukin-1-beta, and interleukin-6 have been shown to correlate strongly with poor outcome in SAH patients. It is unclear what causes this cytokine upregulation, but evidence suggests that Toll-like receptor 4 (TLR4) signalling may be a key player. TLR4 signalling is known to activate cytokine production by macrophages and microglia, though it may also do this in endothelial, smooth muscle, and neuronal cells. Additionally, TLR4 has been implicated in poor outcome in other cerebrovascular disorders, such as intracerebral hemorrhage and ischemic stroke, with genetic and pharmacological suppression of the receptor significantly improving outcome. Our goals are to 1) elucidate the role of TLR4 signalling in poor outcome after SAH using TLR4-knockout mice, 2) identify the key cell types and molecules involved in the pro-inflammatory response to SAH using immunohistochemistry, flow cytometry, qRT-PCR, and ELISA cytokine array, and 3) to demonstrate that pharmacological inhibition of this pathway is feasible and beneficial for animals undergoing experimental SAH. We anticipate that this work will provide more support for the role of TLR4 in mediating the secondary complications after SAH.
Competitiondate
201412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Brathwaite, Shakira
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~